No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing
Douglas F. Easton(University of Cambridge), Montserrat García‐Closas(Institute of Cancer Research), Volker Arndt(German Cancer Research Center), Angela Cox, Francesca Damiola(Centre Léon Bérard), Matthias W. Beckman(Universitätsklinikum Erlangen), Brennan Decker(Boston Foundation), Natalia Bogdanova(Medizinische Hochschule Hannover), Peter A. Fasching(Universitätsklinikum Erlangen), Jenny Chang‐Claude(Universität Hamburg), Simon S. Cross(University of Sheffield), Shahana Ahmed(University of Cambridge), William J. Blot(Shanghai Cancer Institute), Jonine D. Figueroa, Nivonirina Robinot(Centre international de recherche sur le cancer), Joe Dennis(University of Cambridge), Karen A. Pooley(University of Cambridge), Caroline Baynes(University of Cambridge), Mikael Eriksson(Herlev Hospital), Kamila Czene(Karolinska Institutet), Jamie Allen(University of Cambridge), Ella R. Thompson(Peter MacCallum Cancer Centre), Kyriaki Michailidou(Cyprus Institute of Neurology and Genetics), Catherine Voegele(Centre international de recherche sur le cancer), Peter Devilee(Leiden University), Craig Luccarini(University of Cambridge), Nathalie Forey(Centre international de recherche sur le cancer), Javier Benı́tez(Spanish National Cancer Research Centre), Robert Luben(University of Cambridge), Ji‐Yeob Choi(Seoul National University), Mitul Shah(University of Cambridge), Stig E. Bojesen(University of Copenhagen), Kee Seng Chia(National University of Singapore), Hermann Brenner(Universidad de Granada), Hoda Anton‐Culver(University of California, Irvine), Geoffroy Durand(Centre international de recherche sur le cancer), Fabienne Lesueur(Inserm), David Van Den Berg(University of Southern California), Don Conroy(University of Cambridge), Jun Li(Tongji University), Jamil Ahmad(Balochistan University of Information Technology, Engineering and Management Sciences), Kristiina Aittomäki(University of Helsinki), Hatef Darabi, Noura Mebirouk(Inserm), Henrik Flyger(Herlev Hospital), Maroulio Pertesi(Centre international de recherche sur le cancer), Manjeet K. Bolla(University of Cambridge), Florentia Fostira(National Centre of Scientific Research "Demokritos")
Cited by 104
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k